MRD & Disease Monitoring Archives

March 30, 2022

ASH 2021: Dr. Bill Wierda Discusses Outcomes of Adding Oral Venetoclax (Ven) to Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Currently Receiving Oral Ibrutinib (Ibr).

At the annual meeting of the American Society of Hematology (ASH) 2021, Dr. Mathew Davids from the Dana-Farber Cancer Institute in Boston interviews Dr. Bill Wierda from the MD Anderson Cancer Center in Houston. They discuss the benefits of combined finite therapy to achieve U-MRD with a

November 22, 2021

Achieving Innovation in CLL Care Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management

Join CLL Society and PeerView Institute to watch the ASH 2021 Symposium about the newest data on BTK inhibitors and CAR-T cell constructs in CLL Treatment.

June 24, 2021

ASH 2020: Dr. Davids Discusses Duvelisib and Venetoclax, an All-Oral Time-Limited Treatment for Chronic Lymphocytic Leukemia (CLL)

The team at Dana-Farber Cancer Institute is testing whether the combination of duvelisib (Copiktra™) and venetoclax (Venclexta®) will lead to deep remissions that would allow for oral only therapy of one year duration. Learn more about this ongoing Phase I/II clinical trial.

June 24, 2021

ASH 2020: Dr. Furman Discusses Minimal Residual Disease-Driven Captivate and Murano Studies in Chronic Lymphocytic Leukemia (CLL)

The treatment landscape for those of us with CLL/SLL has changed dramatically in the past decade or less. We see decreasing reliance on chemoimmunotherapies that were the only option in the past. We have seen a move from sequential use of targeted therapies to control our CLL to combinations

June 17, 2021

ASH 2020: Dr. Paolo Ghia on the Benefits of Individualized Treatment Plans for Chronic Lymphocytic Leukemia (CLL)

At the annual meeting of the American Society of Hematology (ASH) 2020, our own Dr. Brian Koffman interviewed Dr. Paolo Ghia, Director of the Strategic Research Program on CLL at Università Vita-Salute San Raffaele in Milan, Italy. They discussed results from a clinical trial which individually tailored treatment plans

June 2, 2021

ASH 2020: Dr. Jennifer Woyach on Triple Combination Therapy for Chronic Lymphocytic Leukemia (CLL)

Bruton’s tyrosine kinase (BTK) inhibitors such as ibrutinib and acalabrutinib have been wonderfully effective drugs for treating chronic lymphocytic leukemia (CLL). However, on their own they must be taken continuously and do not produce deep enough remissions to warrant stopping treatment.

March 1, 2021

Testing for Measurable (Minimal) Residual Disease (MRD) in CLL (Chronic Lymphocytic Leukemia) Down to One in One Million Cells Just Got Easier

Flow cytometry is the standard test to look for Measurable (Minimal) Residual Disease (MRD) in CLL and it can find one cancer cell in 10,000 by looking at the telltale combination of surface markers that are found on CLL cells but not on normal cells. Many labs can perform

January 29, 2021

ASH 2020: Dr. William Wierda on minimal residual disease (MRD)-guided discontinuation of ibrutinib + venetoclax in chronic lymphocytic leukemia (CLL)

September 24, 2020

Access to MRD Testing

We asked members of the MRD Testing Collaborative what they think the biggest barriers are to MRD testing. Here’s what they had to say…

MRD & Disease Monitoring

ASH 2021: Dr. Bill Wierda Discusses Outcomes of Adding Oral Venetoclax (Ven) to Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Currently Receiving Oral Ibrutinib (Ibr).

Achieving Innovation in CLL Care Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management

ASH 2020: Dr. Davids Discusses Duvelisib and Venetoclax, an All-Oral Time-Limited Treatment for Chronic Lymphocytic Leukemia (CLL)

ASH 2020: Dr. Furman Discusses Minimal Residual Disease-Driven Captivate and Murano Studies in Chronic Lymphocytic Leukemia (CLL)

ASH 2020: Dr. Paolo Ghia on the Benefits of Individualized Treatment Plans for Chronic Lymphocytic Leukemia (CLL)

ASH 2020: Dr. Jennifer Woyach on Triple Combination Therapy for Chronic Lymphocytic Leukemia (CLL)

Testing for Measurable (Minimal) Residual Disease (MRD) in CLL (Chronic Lymphocytic Leukemia) Down to One in One Million Cells Just Got Easier

ASH 2020: Dr. William Wierda on minimal residual disease (MRD)-guided discontinuation of ibrutinib + venetoclax in chronic lymphocytic leukemia (CLL)

Access to MRD Testing

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT